Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.

Young, R J

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. [electronic resource] - British journal of cancer Mar 2012 - 1153-9 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1532-1827

10.1038/bjc.2012.50 doi


Angiogenesis Inhibitors--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor--blood
Carboplatin--administration & dosage
Carcinoma, Non-Small-Cell Lung--blood
Clinical Trials, Phase III as Topic
Deoxycytidine--administration & dosage
Etoposide--administration & dosage
Female
Fibroblast Growth Factor 2--blood
Humans
Intercellular Adhesion Molecule-1--blood
Interleukin-8--blood
Lung Neoplasms--blood
Male
Middle Aged
Multicenter Studies as Topic
Multivariate Analysis
Neovascularization, Pathologic--blood
Proportional Hazards Models
Randomized Controlled Trials as Topic
Small Cell Lung Carcinoma--blood
Survival Analysis
Thalidomide--therapeutic use
Treatment Outcome
Vascular Endothelial Growth Factor A--blood
Gemcitabine